Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Clopidogrel on Selexipag PK in Healthy Males
NCT03496506Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Area under the plasma concentration-time profile during a dose interval at Day 10. Started Mar 2018; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03496506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496506.